Microbial production site’s manufacturing capacity to increase by 70% upon completion
Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, viral vaccines, and viral vectors, has officially begun expansion of its large-scale microbial manufacturing facility located at the Billingham, UK campus.
To accommodate the increasing demand for the CDMO’s microbial development and manufacturing services, the expansion will feature 20,000 square feet of modular clean room space, including two primary recovery and refolding suites, two purification suites, and a column packing room. The new space is designed to maximize its proprietary SymphonX technology for clinical and commercial manufacturing. Once the expansion is completed in late 2023/early 2024, the manufacturing capacity of the large-scale microbial production facility will increase by 70%.
“Through innovation and the utilization of high-throughput technologies, we continually strive to increase our renowned microbial process development services to complement our extensive manufacturing experience,” comments Paul Found, COO at Fujifilm Diosynth Biotechnologies' UK site.